1. Home
  2. CRSR vs DSGN Comparison

CRSR vs DSGN Comparison

Compare CRSR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corsair Gaming Inc.

CRSR

Corsair Gaming Inc.

HOLD

Current Price

$6.31

Market Cap

616.0M

Sector

Technology

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.45

Market Cap

579.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSR
DSGN
Founded
1994
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
616.0M
579.9M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
CRSR
DSGN
Price
$6.31
$12.45
Analyst Decision
Buy
Strong Buy
Analyst Count
7
4
Target Price
$8.50
$15.25
AVG Volume (30 Days)
999.4K
262.1K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
87.37
N/A
EPS
N/A
N/A
Revenue
$1,472,480,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.86
N/A
52 Week Low
$4.48
$3.11
52 Week High
$10.29
$12.98

Technical Indicators

Market Signals
Indicator
CRSR
DSGN
Relative Strength Index (RSI) 66.67 61.33
Support Level $6.09 $9.71
Resistance Level $6.94 N/A
Average True Range (ATR) 0.22 0.58
MACD 0.09 0.10
Stochastic Oscillator 99.57 75.37

Price Performance

Historical Comparison
CRSR
DSGN

About CRSR Corsair Gaming Inc.

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: